Botulinum shows promise for added urologic indications
Jena, Germany-Botulinum toxin has shown promise as a potential therapy for chronic pelvic pain and lower urinary tract dysfunction. In a German study, injection of botulinum toxin type A into the urethral sphincter muscle led to improvement in muscle tone, pain, and urodynamic parameters in patients enrolled.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.